AAN 2022 | Discussing the future of aducanumab in dementia care at AAN 2022

Joyce Lee-Iannotti, MD, The University of Arizona, Phoenix, AZ, shares the aims of a highly anticipated session at the AAN 2022 Annual Meeting, focused on the approval of aducanumab for patients with dementia. Dr Lee-Iannotti notes that the controversy surrounding the expedited approval of aducanumab and questions regarding its clinical benefits and safety have left many neurology professionals unsure if it should be offered to their patients. The session with Prof. David Knopman aims to discuss the details of the approval process and address questions on the future of dementia care. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.